Serrated lesions

Serate lesions (sawtooth lesions, sawtooth ademones, serate adenomas) are a group of colon adenomas, which probably result in at least a third of all colorectal cancers (data in the literature vary). Serate lesions were first described by Longacer and Fenoglio-Preiser in 1990 as the result of an analysis of a group of colorectal polyps with mixed hyperplastic polyp and adenoma properties. Serate lesions have several subtypes that differ in the risk of developing malignancy. The serate lesion owes its name to the fact that the epithelium of the crypt resembles a saw blade in its arrangement, more precisely the prominent epithelial cells resemble saw teeth. This characteristic arrangement is mainly due to a disorder of apoptosis. According to histological morphology, seratic lesions are classified according to WHO (2010) as follows: 1The terms adenoma and polyp are used, at least in English-written texts, as synonyms.
 * hyperplastic polyp (HP, HPP)
 * sessile seren adenoma / polyp1 (SSA/P)
 * - without cytological dysplasia
 * - with cytological dysplasias (SAAD)
 * traditional seratic adenoma (TSA)

Sporadic hyperplastic polyps, which account for up to 90% of all serous lesions, are unlikely to pose a risk of progression to colorectal cancer. Both severe seratic adenomas and traditional seratic adenomas present a risk of developing colorectal cancer, which is probably higher than in the case of conventional adenomas.

The molecular mechanism of serate lesions and possible malignancy is different from the traditional adenoma-carcinoma pathway, which involves mutation in the APC gene, ias well as from the direct mutation in mutator genes, that causes Lynch syndrome. There is talk of a serate pathway leading to cancer with a hypermethylation phenotype. Mutations in KRAS or BRAF, protein kinases involved in the MAPK signaling pathway, appear to be a key step in the serate pathway, followed by variously expressed hypermethylation of CpG islands in the regulatory regions of mutator genes, resulting in the so - called CIMP phenotype (CpG Island Methylated Phenotype). This results in a decrease in the expression of repair proteins and the cell becomes more susceptible to further somatic mutations. The exact sequence of mutations and disorders during the serous pathway is not known; it is likely that these are several partially linked pathways. The following phenotypes of colorectal cancers are usually distinguished, initiated by serial lesions:
 * 1) BRAF mutation and significant CpC methylation (CIMP-H)
 * 2) associated with marked microsatellite instability (MSI-H)
 * 3) associated with microsatellite stability (MSS)
 * 4) KRAS mutation and low CpC methylation (CIMP-L), microsatellite stability (MSS)

Although these are actually two pathways, one of which branches further, there is talk of a serous pathway of colorectal cancer to express its difference from the pathway of carcinoma in the conventional adenoma-carcinoma sequence and from the development of tumors in Lynch syndrome.

Related Articles

 * Serial lesions / PGS
 * Colorectal cancer
 * Treatment of liver metastases in colorectal cancer
 * Vienna Classification of Gastrointestinal Neoplasias (2002)